Find the latest Malvern news, including product launches, application stories and technology announcements.

Search for press releases

Items shown: 5 , 10 , 20 , ALL
Previous page Showing results 1 - 5 of 10 Next page
  • Malvern Instruments to present at Inkjet Ink Development Conference February 20 2017 - Ref No: PR170220 The IMI Europe Inkjet Ink Development Conference is aimed at ink development chemists looking to find out the latest products, technology and techniques, and exchange ideas with peers. The conference covers colorants, material dispersions, resins and polymers, photoinitiators, ink additives and other materials, analytical equipment and processing techniques.. As part of the conference program, Mats Larsson from Malvern Instruments, will be talking about Ink rheology and why it is important, not only for the jetting process, but also for the formulation, stability and manufacturing of inks. Mats has more than 35 years’ experience in rheology and rheological measurements. . For more details on the conference program and to register for the event click here. By using the code IJID200 when registering (and mentioning Malvern Instruments) registrants can get a €200 discount from the registration fee.. Read more
  • Malvern launches MicroCal PEAQ-DSC February 21 2017 - Ref No: PR3217 The new MicroCal PEAQ-DSC microcalorimeter from Malvern Instruments resets the performance standard for characterizing protein and biomolecule stability. This latest innovation in Differential Scanning Calorimetry (DSC) has been created specifically for the regulated environment and delivers essential data to guide biopharmaceutical development, from protein engineering, through pre-formulation and process development, to formulation and manufacture of the final product.. The new system offers developers a quick stability assay to identify biotherapeutics with good stability potential and enables them to determine the conditions that maximize the shelf-life of a biotherapeutic. In manufacturing, it helps maximize yields of biotherapeutic compounds and supports the robust demonstration of batch-to-batch comparability or innovator to biosimilar comparability.. MicroCal PEAQ-DSC delivers unattended 24-hour operation, together with streamlined workflows and automated data analysis to produce results in hours, driving productivity and efficiency gains in research and production. In addition, the system is network-ready, and has built-in automated cleaning and self-validation protocols that minimize downtime and ensure that all data reported is of the highest quality. Dedicated instrument standards are available so that performance can be validated throughout a series of runs.. Importantly, MicroCal PEAQ-DSC is available with full documentation and software support for Analytical Equipment Qualification, in line with USP and FDA guidance, as well as a comprehensive package to aid technical compliance to FDA CFR Part 11 and EU GMP Annex 11.. Ronan O’Brien, Head of Business Development – MicroCal at Malvern, said: “We are very excited to be putting such a capable tool in the hands of our customers. We have worked closely with users of our previous-generation DSC system to make sure that the MicroCal PEAQ-DSC supports a wide range of needs across the biopharma development cycle. As the importance of biopharmaceuticals continues to grow, we see customers searching for powerful analytical systems that can deliver data that genuinely informs development, formulation and process decisions, as well as supporting regulatory challenges. DSC has long been considered the gold standard for stability measurement but now, with the new MicroCal PEAQ-DSC, we believe we have redefined what is possible with this technique.”. MicroCal PEAQ-DSC is available in two versions: a standalone instrument that includes the DSC cell and a dedicated computer, or a fully automated system with the addition of a liquid handling robot. Either can be specified with the 21 CFR Part 11 software package.. For more information about MicroCal PEAQ-DSC, please visit: . Malvern, Malvern Instruments are registered trademarks of Malvern Instruments Ltd . MicroCal is a trademark of Malvern Instruments Ltd. Read more
  • Aimil Ltd is appointed as the authorized representative for PANalytical in India March 3 2017 - Ref No: PR3421 As of 1st January 2017, Aimil Ltd, has been appointed as the authorized representative for PANalytical’s benchtop X-ray fluorescence spectrometers, Claisse fusion instruments and flux as well as ASD near-infrared products within India. Aimil Ltd, the leading provider of state-of-the-art Instruments and related services, is also a long-term partner of Malvern Instrumentations in India. . Also on 1st January 2017, Malvern and PANalytical merged their activities. Malvern and PANalytical are owned by parent company Spectris plc and are operating companies within the Materials Analysis segment of Spectris. Both companies are world leading suppliers of analytical instrumentation; PANalytical for X-ray instrumentation and software for the purpose of materials analysis and Malvern Instruments for materials and biophysical characterization technology. . The combined entity is a strong player in the materials characterization market and will be able to leverage the strengths of the individual companies in their end markets ranging from building materials to pharmaceuticals and from metals and mining to nanomaterials. . “The appointment of Aimil Ltd as the agent of both Malvern and PANalytical is timely. Aimil will bring greater synergy to India. They will be able to offer a holistic range of products, solutions and services to a broader set of markets and customers” says Gjalt Kuiperes, Regional Director for Malvern & PANalytical Asia Pacific. . “The merger of PANalytical and Malvern is a great move forward. We at Aimil, are very excited to work with world-renowned PANalytical X-ray products to address existing and emerging markets more comprehensively. I can assure you our teams will do justice to this confidence” comments Arvind Verma, Managing Director for Aimil Ltd. . Read more
  • Malvern Panalytical embraces the Internet of Things with TetraScience partnership for smart laboratories August 8 2017 - Ref No: PRTetra Malvern Panalytical, a global leader in analytical characterization technology development, has announced a collaboration with specialist Internet of Things (IoT) company, TetraScience, to deploy IoT-enabled capabilities and connectivity for its instruments. The objective of the collaboration will be to provide access to customized dashboards, data collection and analytics, and system scheduling and monitoring. This will allow researchers – particularly those working in the pharmaceutical industry and other sectors involved in the creation of complex materials – to improve laboratory efficiency, better manage their equipment, and make swift, data-driven decisions. . The first phase of this collaboration will focus on connecting the Empyrean (X-ray diffraction) and Mastersizer 3000 (laser diffraction) instruments via the TetraScience platform. This capability will enable both availability and usage reporting for these systems, and also their remote monitoring by scientists, who can make adjustments when they are alerted that parameters are beginning to deviate from established criteria. Malvern Panalytical’s customers will be able to securely and seamlessly access both instrumentation and data via a customized web-based dashboard. This will allow key laboratory stakeholders to perform higher-quality measurements, increase instrument uptime, prevent failures, and better tailor their service contracts based on real usage data. . Lindsey Christensen, Director of Marketing, TetraScience, commented: “Many companies struggle with the quantity of data produced, with data analytics, and with bottlenecks of various kinds in laboratory operations. Modern technologies, like the Internet of Things, are a critical means of alleviating these challenges. We selected Malvern Panalytical as our partner in this collaboration as they are the most forward-looking manufacturer of materials analysis systems. The Malvern Panalytical brand represents quality and precision and is the standard in many parts of scientifically-focused R&D, such as pharmaceutical development and manufacture.” . Duncan Roberts, V. P. Business Development, Malvern Panalytical, commented: “We have been closely engaged in finding the most suitable way to help our customers benefit from the vast potential offered by the Internet of Things. It was important for us to work with a leader in the IoT field, and we chose the TetraScience platform because it is robust, easy-to-use and vendor-agnostic. This means that our customers will be able to connect Malvern Panalytical instruments, as well as others within their labs, to create a holistic, interconnected view of laboratory efficiency. We have been impressed with the flexibility of the TetraScience platform and its ability to deal with the complexities of modern research processes – particularly for discovery and development workflows in the pharmaceutical industry.” . Malvern Panalytical’s systems are used by scientists and engineers in a wide range of industries, ranging from building materials to pharmaceuticals and from metals and mining to nanomaterials. They reliably address a wide variety of measurement and characterization needs and are underpinned by extensive industry knowledge, technical expertise and applications understanding. . Malvern Panalytical is part of Spectris plc. Malvern Panalytical and TetraScience will be holding a joint webinar in the coming weeks to provide more detail about their partnership. Contact to register your interest.. Read more
  • Towards a Condensed Platform for Protein Aggregation Profiling December 4 2017 - Ref No: PR171204MPBio Malvern Panalytical announces the launch of a collaborative project which aims to support the development of existing and next generation biopharmaceutical products. . The company led a competitive funding application for analytical technologies for biopharmaceutical development which drew participation from leading bioscience organisations and responds to current industry challenges surrounding aggregation characterization. The successful bid resulted in funding of the associated costs of £1 million for the 3-year-long project, with a grant from the UK’s innovation agency, Innovate UK. . From June 1st, 2017, Malvern Panalytical began leading a working consortium comprising the following partner organisations: The Centre for Process Innovation (CPI), Paraytec Ltd., the University of Central Lancashire (UCLan) and GSK, MedImmune, and Fujifilm Diosynth Biotechnologies representing the biopharmaceutical industry. . The costs associated with the development and production of safe and effective biopharmaceuticals continue to limit their vast potential in treating and preventing disease. Malvern Panalytical has long been involved in addressing the specific analytical challenges of this field, where biomolecule stability and successful formulation are paramount. The company has tailored its proven solutions to the needs of biological molecules, developed groundbreaking new technologies and been involved in other industry-wide collaborations to advance biopharmaceutical development and manufacturing knowledge. Malvern Panalytical’s evolving suite of instruments delivers an array of biophysical information, helping biopharmaceutical developers reduce risk and increase efficiency and speed to market. . Protein-based pharmaceuticals are often susceptible to instability that can cause drug molecules to aggregate, which may result in a reduction of their therapeutic effectiveness and possibly in unwanted side-effects in the patient. Aggregation is therefore viewed as a high-risk issue in biopharmaceutical development. With the new analytical technology that will result from this collaborative project, the consortium aims to attenuate the risks associated with aggregation to ensure the delivery of safe and cost-effective drugs in the future. . Dr. Steve Carrington, Head of Biophysical Characterization at Malvern Panalytical, said: “The collaborative consortium leading this project has been specifically gathered together to provide expertise across all stages of biopharmaceutical discovery and development, in order to address the challenges of developing the wider scope of relevant and rationalized aggregation analytics.” . “We are delighted to have been given the opportunity to work hand-in-hand with our partners in the biopharmaceutical industry, and also in small business and academia, on such an important project. Our industrial colleagues are providing invaluable insight into the development challenges they as biopharmaceutical developers face, then providing the facility to test new solutions in real-world scenarios.” added Dr. Carrington. . “Our collaboration with the School of Pharmacy and Biomedical Sciences at UCLan will help inspire and engage the scientists of the future, as they see for themselves how new analytical technology can be applied to understand the behavior of novel drugs at near-in vivo conditions,” said Dr. Oksana Barker, Senior Development Scientist at Malvern Panalytical.. Read more
Previous page Showing results 1 - 5 of 10 Next page